asco.org3d
Dr. Rahul Seth Appointed to American Medical Association’s CPT Editorial Panel
Dr. Rahul Seth, left, and Dr. Joseph Merchant attend the February 2025 CPT Editorial Panel meeting in San Jose, California. The American Society of Clinical Oncology (ASCO) congratulates member and ...
asco.org3d
Additional Noteworthy Studies to be Presented During 2025 ASCO Genitourinary Cancers Symposium
ALEXANDRIA, Va. – Nine studies exploring new approaches for the treatment of genitourinary cancers will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Genitourinary ...
asco.org4d
ASCO Wants to Hear from You: Impact of New Policy Change
The National Institutes of Health (NIH) announced a new policy on February 7, 2025, capping the indirect cost rate for all research grants at 15%. According to NIH, this cap applies to all new and ...
asco.org5d
Mobile Prostate Cancer Screening Clinic Can Help Address Barriers to Serving High-Risk Communities
“This research intervention to improve health equity and reduce cancer disparities shows that we can meet underserved populations where they live and improve their health and healthcare,” said ...
asco.org2d
Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Development of a pan-cancer 15 gene expression signature to detect a subgroup driven by EMT/MAPK signalling.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2d
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...